By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Researchers detail new data in Biotechnology. According to news originating from New York City, New York, by NewsRx correspondents, research stated, "Gene therapy for heart failure treatment is currently being optimized and validated. The results to date are encouraging but challenges remain before it becomes a therapeutic approach in clinical cardiology."
Our news journalists obtained a quote from the research from Cardiovascular Research Center, "Much effort is dedicated to improve gene transduction efficiency by improving the vectors and the delivery methods. Successful translation from the benchtop to the bedside requires teams including biologists focusing on vector modification and cardiologists refining delivery methods. Two key components for translation to the clinic include safety and efficacy. Transduction efficiency is closely linked to invasiveness in most delivery methods. However, current candidates for cardiac gene therapy are patients without effective treatment option and are in advanced heart failure, thus a less invasive approach is preferred."
According to the news editors, the research concluded: "This review focuses on injection methods of gene delivery with emphasis on percutaneous and endovascular approaches to summarize currently available percutaneous gene delivery methods and their features."
For more information on this research see: Percutaneous approaches for efficient cardiac gene delivery. Journal of Cardiovascular Translational Research, 2013;6(4):649-59. Journal of Cardiovascular Translational Research can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. (Springer - www.springer.com; Journal of Cardiovascular Translational Research - www.springerlink.com/content/1937-5387/)
The news correspondents report that additional information may be obtained from K. Ishikawa, Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY 10029-6574, United States. Additional authors for this research include J. Aguero, C. Naim, K. Fish and R.J Hajjar (see also technology.html">Biotechnology).
The publisher's contact information for the Journal of Cardiovascular Translational Research is: Springer, 233 Spring Street, New York, NY 10013, USA.
Keywords for this news article include: Biotechnology, Treatment, Cardiology, Gene Therapy, New York City, United States, Bioengineering, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC